In early, levodopa-naive PD patients, Stalevo induced more dyskinesia than similar dosages of levodopa/carbidopa, so the regimen tested (target maintenance dose Stalevo 100 four-times daily given ...

ion.ucl.ac.uk OBJECTIVES New treatments are now becoming available for the management of levodopa induced dyskinesias in Parkinsons's disease. However, assessment of their efficacy is limited by the ...

Vistagen , a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced ...

Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb ...

Therapeutic window of patients relying on it narrow by time, and eventually motor syndromes will develop, notably levodopa-induced dyskinesias (Del Sorbo and Albanese, 2008). Furthermore, the use of ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...